Comparative Pharmacology
Head-to-head clinical analysis: MAOLATE versus NORGESIC FORTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAOLATE versus NORGESIC FORTE.
MAOLATE vs NORGESIC FORTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MAOLATE is a centrally acting muscle relaxant that does not directly relax skeletal muscle. Its mechanism of action is not fully understood, but it is thought to act via inhibition of polysynaptic reflexes at the spinal level and possibly through sedation.
Norgesic Forte is a combination of orphenadrine citrate and aspirin (acetylsalicylic acid). Orphenadrine is a centrally acting muscle relaxant with anticholinergic and antihistaminic properties; it acts via blockade of nicotinic acetylcholine receptors at the neuromuscular junction and centrally as a non-competitive antagonist at NMDA receptors, reducing hypertonicity and spasm. Aspirin provides analgesic and anti-inflammatory effects via irreversible inhibition of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis.
250 mg orally 4 times daily or 500 mg orally 3 times daily for 21 days; maximum daily dose 2000 mg.
1 tablet orally 3 times daily. Each tablet contains orphenadrine citrate 100 mg and paracetamol 500 mg.
None Documented
None Documented
Terminal elimination half-life: 8-12 hours (prolonged in renal impairment, up to 20-30 hours in severe renal failure; dose adjustment required for CrCl <30 mL/min)
Terminal elimination half-life: 4-6 hours; in elderly or hepatic impairment, half-life may be prolonged up to 12 hours, necessitating dose adjustment.
Renal: ~70% as unchanged drug and metabolites; Biliary/Fecal: ~30%
Renal (70% as unchanged drug and conjugates), fecal (20%), biliary (10%)
Category C
Category C
Muscle Relaxant
Muscle Relaxant